• 1
    Sastry KSR, Haydock C, Basha AM, Rao DV. Electron dosimetry for radioimmunotherapy: optimal electron energy. Radiat Prot Dosimetry 1985; 13: 24952.
  • 2
    Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med 1994; 35: 52130.
  • 3
    O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 19029.
  • 4
    Willins JD, Sgouros G. Modeling analysis of platinum-195m for targeting individual blood-borne cells in adjuvant radioimmunotherapy. J Nucl Med 1995; 36: 3159.
  • 5
    Sharkey RM, Kaltovich FA, Shih LB, Fand I, Govelitz G, Goldenberg DM. Radioimmunotherapy of human colonic cancer xenografts with 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988; 48: 32705.
  • 6
    DeNardo GL, Kukis DL, Shen S, Srivastava SC, Miers LA, DeNardo SJ. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3: 719.
  • 7
    Behr TM, Sgouros G, Vougioukas V, Memtsoudis S, Gratz S, Schmidberger H, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76: 73848.
  • 8
    Goddu SM, Howell RW, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S values. Reston, VA: Society of Nuclear Medicine, 1997.
  • 9
    Warters RL, Hofer KG, Harris CR, Smith JM. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr Topics Rad Res Quarterly 1977; 12: 389.
  • 10
    Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212–labeled anti-TAC monoclonal antibody: α-particle–emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad. Sci U S A 1986; 83: 4748.
  • 11
    Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999; 40: 16676.
  • 12
    Atcher RN, Friedman AM, Hines JJ. An improved generator for the production of Bi-212 from Ra-224. Appl Radiat Isot 1988; 39: 2836.
  • 13
    Boll RA, Mirzadeh S, Kennel SJ. Optimization of radiolabeling of immunoproteins with 213Bi. Radiochim Acta 1997; 79: 1459.
  • 14
    Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 581820.
  • 15
    McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An α-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60: 60956100.
  • 16
    Schwarz UP, Plascjak P, Beitzel MP, Gansow OA, Eckelman WC, Waldmann TA. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol 1998; 25: 8993.
  • 17
    Lindegren S, Andersson H, Bäck T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labeling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol 2001; 28: 339.
  • 18
    Howell RW. Radiation spectra for Auger-electron emitting radionuclides. Report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992;19: 137183.
  • 19
    Cole A. Absorption of 20 eV to 50,000 eV electron beams in air and plastic. Radiat Res 1969; 38: 733.
  • 20
    Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: radionuclide data and decay schemes. New York: Society of Nuclear Medicine, 1989.
  • 21
    Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with β-particle emitters. J Nucl Med 2000; 41: 208997.
  • 22
    Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res 1989; 49: 29528.
  • 23
    de Leij L, Helrich W, Stein R, Mattes MJ. SCLC-cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer 1994;(Suppl 8): 603.
  • 24
    Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 2001; 7: 192201.
  • 25
    Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125–labeled A33 monoclonal antibody. J Nucl Med 1996; 37: 10527.
  • 26
    Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotoxicity with Auger electron–emitting radionuclides delivered by antibodies. Int J Cancer 1999; 81: 98592.
  • 27
    Ochakovskaya R, Osorio L, Goldenberg D, Mattes M. Therapy of disseminated B-cell lymphoma xenografts in SCID mice with an anti-CD74 antibody conjugated with 111In, 67Ga, or 90Y. Clin Cancer Res 2001; 7: 150510.
  • 28
    Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992; 52: 83542.
  • 29
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995; 55: 31329.
  • 30
    Brady L, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992; 22: 22530.
  • 31
    Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14: 178797.
  • 32
    Snyder WS, Ford MR, Warner GG, Watson SB. “S,” absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet no. 11. Reston, VA: Society of Nuclear Medicine, 1975.
  • 33
    Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41: 170413.
  • 34
    Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55: 382534.
  • 35
    Kraeber-Bodéré F, Mishra A, Thédrez P, Faivre-Chauvet A, Bardiès M, Imai S, et al. Pharmacokinetics and biodistribution of samarium-153–labeled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur J Nucl Med 1995; 23: 5607.
  • 36
    Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995; 55: 87884.
  • 37
    Furukawa T, Fujibayashi Y, Fukunaga M, Saga T, Endo K, Yokoyama A. An approach for immunoradiometric assay with metallic radionuclides: gallium-67-deferoxamine-dialdehyde starch-IgG. J Nucl Med 1991; 32: 8259.
  • 38
    Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, et al. Yttrium-90–labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 45770.
  • 39
    Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 125966.
  • 40
    Bender H, Takahashi H, Adachi K, Belser P, Liang S, Prewett M, et al. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992; 52: 1216.
  • 41
    Sugiyama Y, Chen F, Takita H, Bankert RB. Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody. Cancer Res 1988; 48: 276873.
  • 42
    Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA. Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody. Cancer Res 1985;45: 50807.
  • 43
    Johnson TA, Press OW. Synergistic cytotoxicity of iodine-131–anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 2000; 85: 10412.
  • 44
    Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med 2000; 41: 151921.
  • 45
    Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996; 93: 861823.
  • 46
    Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997; 57: 45306.
  • 47
    Omelyanenko V, Gentry C, Kopecková P, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 1998;75: 6008.
  • 48
    Kassis AI, Fayad F, Kinsey BM, Sastry KSR, Adelstein SJ. Radiotoxicity of an 125I-labeled DNA intercalator in mammalian cells. Radiat Res 1989; 118: 28394.
  • 49
    Mattes MJ, Major PP, Goldenberg DM, Dion AS, Hutter RVP, Klein KM. Patterns of antigen distribution in human carcinomas. Cancer Res 1990; 50(Suppl): 880s884s.
  • 50
    Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial fluid pressure. Cancer Res 1988; 48: 702232.
  • 51
    Fenwick JR, Philpott GW, Connett JM. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake. Int J Cancer 1989; 44: 101727.
  • 52
    Shih L, Ong GL, Burton J, Mishina D, Goldenberg DM, Mattes MJ. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice. Cancer Immunol Immunother 2000; 49: 20816.
  • 53
    Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993; 36: 26773.
  • 54
    Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete response. Cancer Res 1998; 58: 96875.